3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
10
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Uveal Melanoma
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Carcinoma, Basal Cell
2
Advanced Cancer
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Spinocerebellar Degenerations
1
Sarcoma
1
Interventions
Gemcitabine
6
Trastuzumab
4
Carboplatin
3
pembrolizumab
2
Pemetrexed
2
Paclitaxel
2
Cisplatin
2
vinflunine
1
tucatinib
1
relatlimab
1
palbociclib
1
niraparib
1
motexafin gadolinium
1
montanide ISA 51
1
flt3 ligand protein
1
enfortumab vedotin
1
cabozantinib
1
atezolizumab
1
apatorsen
1
abemaciclib
1
Zoledronic Acid
1
Urinary Diversion
1
Therapeutics
1
Thalidomide
1
Sunitinib
1
Radiosurgery
1
Nivolumab
1
Mitomycin
1
MART-1 Antigen
1
Immunoglobulins, Intravenous
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Urologic Neoplasms
×
relatlimab
×
Clear all
NCT06237920
2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2
Recruiting
90 enrolled